Back to today’s briefing

Story perspectives

GeneSight Test Outshines Standard Treatment for Depression

9/4/2025

30 3

Summary

Story summary

A meta-analysis indicates the GeneSight Psychotropic test outperforms standard treatment for major depressive disorder (MDD) after prior failures.
The study included 3,532 adults and evaluated depression severity through established questionnaires.
Myriad Genetics plans to increase patient access to the GeneSight test to enhance depression treatment outcomes.

1 of 1

Story summary

A meta-analysis indicates the GeneSight Psychotropic test outperforms standard treatment for major depressive disorder (MDD) after prior failures.
The study included 3,532 adults and evaluated depression severity through established questionnaires.
Myriad Genetics plans to increase patient access to the GeneSight test to enhance depression treatment outcomes.